Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high210.00 24/10/16
52 week low120.75 17/02/17
52 week change -20.00 (-11.59%)
4 week volume571,864 03/05/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
28/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 4776G Verona Pharma PLC 30 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acqui...

Holding(s) in Company

RNS Number: 4777G Verona Pharma PLC 30 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acqui...

Holding(s) in Company

RNS Number: 2914G Verona Pharma PLC 25 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisi...

Verona Pharma Announces Further Exercise of Over-Allotment Option and Resulting Total Voting Rights

Verona Pharma Announces Further Exercise of Over-Allotment Option and Resulting Total Voting Rights THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ...

Verona CEO to present at Jefferies Healthcare Conference

Verona Pharma has confirmed that Jan-Anders Karlsson, PhD, CEO of the Company, is scheduled to present at the Jeffer...

Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference

Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, an...

Holding(s) in Company

RNS Number: 9441F Verona Pharma PLC 23 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisitio...

Broker Forecast - Jefferies International issues a broker note on Verona Pharma PLC

Jefferies International today initiates coverage of Verona Pharma PLC (LON:VRP) with a buy investment rating and pric...

Fundamental DataMore

EPS-0.74
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • Re: bit of info ATS 2017

    http://markets.ft.com/data/announce/detail?dockey=1323-13206077-742MLB5D0VUOUU219494LO87OG mol
    25-May-2017
    mol42
  • bit of info ATS 2017

    http://www.pharmaceutical-technology.com/comment/commenthighlights-from-the-2017-ats-conference-positive-results-for-astrazenecas-daliresp-beyond-reducing-the-risk-of-exacerbat ...
    25-May-2017
    mol42
  • Re: bit of info - analyst coverage

    more and more info available since launch - which will only increase over the next months http://www.nasdaq.com/symbol/vrna/recommendations well worth keeping an eye on ...
    25-May-2017
    mol42

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.20%
RENEURON10%
RANGE RES.10%
BP10%
GULF KEYSTONE10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP